Cory Abate-Shen, PhD
- Michael and Stella Chernow Professor of Urologic Sciences (in Urology)
- Professor of Pathology and Cell Biology (in the Herbert Irving Comprehensive Cancer Center)
Cory Abate-Shen, Ph.D., joined the faculty of Columbia University Medical Center and the Herbert Irving Comprehensive Cancer Center in 2007. A leader in the field of urological oncology, Dr. Abate-Shen is the Michael and Stella Chernow Professor of Urologic Sciences, director of research in the Department of Urology, and an associate director of HICCC and leader of its Prostate Program.
Dr. Abate-Shen obtained her Ph.D. at Cornell University Medical College, and pursued her postdoctoral training with Tom Curran at the Roche Institute of Molecular Biology. In 1991, she joined the University of Medicine & Dentistry of New Jersey-Robert Wood Johnson Medical School as an assistant professor. She rose to the rank of professor by 2001, and was appointed chief of a new Division in the Department of Medicine in 2002. Dr. Abate-Shen also created the Prostate Program for the Cancer Institute of New Jersey and served as its co-leader from 1999 to 2007.
Among her various honors and awards, she has recently been selected as an American Cancer Society Research Professor, the first ever at Columbia University Medical School.
Dr. Abate-Shen’s research focuses on the molecular mechanisms of cancer development. She has a longstanding commitment to the generation of mouse models of cancer and their effective use for translational research. Her major research interests are in the area of genitourological cancer. Most notably, her laboratory has developed novel models of prostate and bladder cancer, which have been utilized for investigating the molecular basis of the disease as well as preclinical models for evaluating new therapies.
- Molecular mechanisms of cancer development
- Genitourinary cancer development
MITOCHONDRIAL AND NUCLEAR FUNCTIONS OF NKX3.1 IN REGULATING OXIDATIVE STRESS IN PROSTATE CANCER (Federal Gov)
Dec 1 2018 - Nov 30 2023
MODELING BLADDER CANCER PATHOGENESIS AND TUMOR EVOLUTION (Federal Gov)
Sep 11 2018 - Aug 31 2023
PRECLINICAL ANALYSES OF ADVANCED PROSTATE CANCER IN GENETICALLY-ENGINEERED MICE (Federal Gov)
Feb 14 2018 - Jan 31 2023
TARGETING ERCC2 TO OVERCOME CHEMOTHERAPY RESISTANCE IN METASTATIC BLADDER CANCER (Private)
Jul 1 2019 - Jun 30 2021
INVESTIGATING THE CELL OF ORIGIN OF BLADDER CANCER (Federal Gov)
Apr 1 2015 - Sep 30 2020
MOLECULAR MECHANISMS OF PROSTATE CANCER METASTASIS (Federal Gov)
Jan 1 2015 - Jun 30 2020
THE USE OF INTRAVESICAL CABAZITAXEL, GEMCITABINE, AND CISPLATIN (CGC) IN THE TREATMENT OF HIGH RISK NON-MUSCLE INVASIVE BLADDER CANCER (Private)
Jul 1 2012 - Dec 31 2014